Best Vitelliform Macular Dystrophy – Page 37 of 37

References

1. Querques, Giuseppe, Maria C. Angulo Bocco, Gisele Soubrane, and Eric H. Souied. Intravitreal Ranibizumab (Lucentis) for Choroidal Neovascularization Associated with Vitelliform Macular Dystrophy.” Acta Ophthalmologica 86.6 (2008): 694-95.
2. Leu, Jorg, Norbert F. Schrage, and Robert F. Degenring. “Choroidal Neovascularisation Secondary to Best’s Disease in a 13-year-old Boy Treated by lntravitreal Bevacizumab.” Graefe’s Archive for Clinical and Experimental Ophthalmology (2007): 1723-724.
3. G Querques, M Regenbogen, C Quijano, et al. 2008. High-Definition Optical Coherence Tomography Features in Vitelliform Macular Dystrophy. American Journal of Ophthalmology. 146(4): 501-507.
4. G Querques, M Regenbogen. G Soubrane, et al. 2009. High-resolution Spectral Domain Optical Coherence Tomography Findings in Multifocal Vitelliform Macular Dystrophy. Survey of Ophthalmology. 54(2): 311-316.
5. N Puche, G Querques, N Benhamou, et al. 2010. High-resolution spectral domain optical coherence tomography features in adult onset foveomacular vitelliform dystrophy. BrJ Ophthalmol. 94: 1190-1196.
6. K Suk, A Pathengay, H Flynn. 2011. The Clinical Course of Adult “Vitelliform” Macular Lesions. Ophthalmology Management. 50.
7. E Sohn. P Francis, JL Duncan, et al. 2009. Phenotypic Variability Due to a Novel Glu292Lys Variation in Exon 8 of the BEST1 Gene Causing Best Macular Dystrophy. Arch Ophthalmol. 127(7): 913-920.

Suggested Readings

• L Yannuzzi. 2010. The Retinal Atlas. Elsevier Limited. 50-56.